The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come ... Merck would be open to picking up commercial assets as well, he added. The Gardasil move was no doubt ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant ... is not good for the near-term ...

US pharma giant Merck & Co (NYSE: MRK) opened Tuesday’s trading 10% ... According to the company, this sales range reflects a decision to temporarily pause shipments of the HPV vaccine ...

Merck issued guidance for 2025 that lags consensus ... after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine in China overshadowed a quarterly earnings beat.

Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., primarily due to lower ...

Merck (MRK.N), opens new tab said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue ...

By Michael Erman and Mariam Sunny (Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a ...

a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025. Merck reported fourth-quarter revenue and adjusted earnings that topped expectations ...